RAPIBLYK (Phebra Pty Ltd)
Product name
RAPIBLYK
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
78 (120 working days)
Active ingredients
landiolol hydrochloride
Registration type
NCE/ NBE
Indication
RAPIBLYK is indicated in adults for:
- supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
- non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.